Furthermore, among the 18 patients with IP receiving both EGFR-TKIs and nivolumab, the sequence of administration was identified in 15 cases: all were treated with nivolumab followed by EGFR-TKIs. The gene discussed is EGFR; the disease is incontinentia pigmenti.